Premium
Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients
Author(s) -
Kennedy Margaret,
Andreescu Astrid C. M.,
Greenblatt Marc S.,
Jiang Hongyu,
Thomas Christian A.,
Chassereau Laurie,
Wong Cheung,
Durda Peter,
Cushman Mary
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.05327.x
Subject(s) - factor v leiden , odds ratio , medicine , risk factor , confidence interval , gastroenterology , venous thrombosis , cancer , thrombosis , surgery
Summary Cancer patients have an increased risk of venous thrombosis (VT). The association of factor V Leiden (FVL) and the prothrombin 20210A variant with VT in cancer patients is not established. We genotyped 101 cancer patients with VT and 101 cancer patients without VT for these polymorphisms. Five cases and three controls were heterozygous for FVL, yielding an odds ratio of 1·7 (95% confidence interval (CI) 0·3–10·7). Five cases and no controls were heterozygous for prothrombin 20210A, for an odds ratio of 6·7 (95% CI 0·9–infinity). Prothrombin 20210A may be associated with VT risk among cancer patients.